

## **Shared Plans and Legacy Medicaid**

### Prior Authorization Requirement for Omalizumab (Xolair®)

Effective October 15, 2013, pharmacy claims billed for omalizumab (Xolair®) will require prior authorization (PA). Pharmacy claims without a PA will deny with:

**NCPDP rejection code 75 (DUR Reject Error) mapped to**

**EOB code 485 (PA Required)**

Prior authorization may be requested through the Louisiana Medicaid RxPA Operations at the University of Louisiana at Monroe College of Pharmacy. The omalizumab (Xolair®) prior authorization form is available at [www.lamedicaid.com](http://www.lamedicaid.com) following the link for pharmacy and prescribing providers. The form must be completed in full and signed by the prescribing practitioner. Signature stamps and proxy signatures are not acceptable. The completed form must be faxed from the prescribing practitioner to the Louisiana Medicaid RxPA Operations at the University of Louisiana at Monroe College of Pharmacy at 1-866-797-2329. Please refer to [www.lamedicaid.com](http://www.lamedicaid.com) for complete PA instructions.

Medical reconsideration of a prior authorization decision may be requested by the prescribing practitioner. To request reconsideration, the *Request for Reconsideration* form must be completed in full and signed by the prescribing practitioner. Signature stamps and proxy signatures are not acceptable. The completed form must be faxed from the prescribing practitioner to the Louisiana Medicaid RxPA Operations at the University of Louisiana at Monroe College of Pharmacy at 1-318-812-2940.

**FAX OR MAIL this form to:**  
 La Medicaid Rx PA Operations  
 ULM College of Pharmacy  
 1800 Bienville Drive  
 Monroe, LA 71201-3765  
 FAX 866-RX PAFAX  
 FAX 866-797-2329

**State of Louisiana**  
**Department of Health and Hospitals**  
 Bureau of Health Services Financing  
 Louisiana Medicaid Prescription Prior Authorization Program  
**REQUEST FOR XOLAIR (OMALIZUMAB) PRIOR AUTHORIZATION**

Form: Rx PA06  
 Issue Date: 3/01/2013

Voice Phone:  
 866-730-4357

*Please type or print legibly. Incomplete forms will not be approved.*

Date of Request		Number of Fax Pages	
<b>Prescribing Provider Information</b>		<b>Recipient Information</b>	
Name (Last, First)		Name (Last, First)	
LA Medicaid Prescribing Provider Number / NPI		LA Medicaid CCN or Recipient Number	
Provider Specialty		Date of Birth (mm/dd/yy)	
Call-Back Phone Number (include area code)		Recipient Weight (kg)	
FAX Number (Include area code)		Recipient Height (ft / in)	
Office Contact Name		Medication Allergies	
<b>Requested Drug Information</b>			
Initiation of Therapy <input type="checkbox"/> Continuation of Therapy <input type="checkbox"/>		Projected Duration of Treatment	
Drug Name	Drug Strength	Dosage Form	Dosage Interval (sig)
Diagnosis Code (ICD -9-CM) Relevant for this Request		Diagnosis Description	Quantity

**Please answer the following questions for your request to prescribe this medication for your patient:**

1. Xolair dosage will be \_\_\_\_\_ mg SQ every: ☐ 2 WEEKS ☐ 4 WEEKS  
 (choose one)

2. Indication criteria: (Must meet all of the following for consideration)

- ☐ Diagnosis of Moderate to Severe Persistent Asthma
- ☐ Age > or = to 12 years old
- ☐ Elevated IgE level: \_\_\_\_\_
- ☐ Inadequate response to medium to high dose inhaled corticosteroids PLUS inhaled long acting beta agonist OR leukotriene modifier: (list below)
- Drug \_\_\_\_\_ Dosage \_\_\_\_\_ Duration of therapy \_\_\_\_\_
- Drug \_\_\_\_\_ Dosage \_\_\_\_\_ Duration of therapy \_\_\_\_\_

**Practitioner Signature:** \_\_\_\_\_

*(If a signature stamp is used, then the prescribing practitioner must initial the signature.)*

**CONFIDENTIAL NOTICE**

*The documents accompanying this facsimile transmission may contain confidential information which is legally privileged. The information is intended only for the use of the individual or entity to which it is addressed. If you are not the intended recipient you are hereby notified that any review, disclosure/re-disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy this information.*